Researchers say the findings counter a common belief that new oncology drugs often win approval in Europe first.
The study shows new cancer medications typically reach the U.S. market several months before they are available to patients in Europe.
The Food and Drug Administration has been criticized by some manufacturers as being too cautious in analyzing drugs as well as medical devices.
